Acute Myeloid Leukemia (AML)
Shannon McCurdy, MD
Rigosertib in Combination With Azacitidine in Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia: Results of a Phase 1 Study
Phase 1 results from a Phase 1/2 study comprise 18 patients with myelodysplastic syndromes myelodysplastic syndromes: (my-eh-
Sarah Bannon, MS, CGC
Mary K. Hughes, MS, RN, CNS, CT
Immunomodulation With Pomalidomide at Early Lymphocyte Recovery After Induction Chemotherapy in Newly Diagnosed AML and High-Risk MDS
An immunosuppressive microenvironment promoting leukemia cell immune escape plays an important role in the pathogenesis of AML. Through its interaction with cereblon, a substrate receptor for the E3 ubiquitin ligase complex, pomalidomide leads to selective ubiquitination of transcription factors Aiolos and Ikaros thereby promoting immune modulation.
External Resources
This is a list of many resources that may be helpful to patients and their families dealing with a bone marrow failure bone marrow failure: A
